BioPharma Dive June 20, 2024
Jonathan Gardner

One-year study data showing PTC’s pill suppressed a key protein helped persuade the regulator to remove a partial clinical hold it had put in place in 2022.

Dive Brief:

  • PTC Therapeutics said Thursday it can resume a Phase 2 trial of its Huntington’s disease drug in the U.S., following the Food and Drug Administration’s review of data showing the pill reduced a mutant protein linked to the disorder.
  • The drug, called PTC518, suppressed levels of huntingtin protein in both the blood and the cerebrospinal fluid by 43% in patients who took a once-daily 10 milligram dose over 12 months, PTC said. The company had previously disclosed data showing that dose reduced blood levels by around 30% through 12 weeks.
    • ...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Clinical Trials, FDA, Govt Agencies, Pharma, Pharma / Biotech, Trends
Related Articles:
What A Potential FDA Red Dye No. 3 Ban Could Mean For Public Health
STAT+: Former Trump FDA, CMS heads lay out how his return could reshape health policy
The Overdue Imperative Of Cross-Racial Pulse Oximeters
FDA’s evolving regulatory framework for AI use in drug & device clinical trials and research
FDA has approved over 1,000 clinical AI applications, with most aimed at radiology

Share This Article